Tissue-specific inactivation of p53 tumor suppression in the mouse

Tammy Bowman, Holly Symonds, Liya Gu, Chaoying Yin, Moshe Oren, Terry Van Dyke

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The p53 gene is the most frequent target of structural and functional genetic mutations in human cancer. Thus, considerable effort has been devoted to mapping the functional domains of p53 with regard to their impact on tumorigenesis in vivo. Studies have shown that the carboxy-terminal domain of p53 is sufficient for transformation in vitro. To determine whether a transdominant-negative p53 protein could be used to elicit a tissue-specific p53-null effect in vivo, we tested whether a carboxy-terminal p53 fragment (amino acids 302-390) could abolish p53-dependent apoptosis in an established tumor progression model. We showed previously that loss of p53-dependent apoptosis accelerates brain tumorigenesis in a transgenic mouse model. Here, we show that the same effect can be elicited by expressing a dominant- negative p53 protein tissue specifically in the presence of wild-type p53. Transgenic mice in which pRb function has been disrupted and that coexpress a p53 carboxy-terminal dominant-negative fragment (p53DD) develop aggressive brain tumors mimicking genetic loss of p53 in this model. Inactivation of endogenous p53, which we show to be complexed with p53DD, results in a reduction in apoptosis and acceleration of tumorigenesis. These studies establish a mechanism for tissue-specific knock out of p53 function in vivo.

Original languageEnglish (US)
Pages (from-to)826-835
Number of pages10
JournalGenes and Development
Volume10
Issue number7
DOIs
StatePublished - Apr 1 1996

Fingerprint

Carcinogenesis
Apoptosis
Transgenic Mice
Neoplasms
p53 Genes
Brain Neoplasms
Proteins
Amino Acids
Mutation
Brain
In Vitro Techniques

Keywords

  • apoptosis
  • cancer
  • cell specificity
  • p53
  • transgenic mice

ASJC Scopus subject areas

  • Genetics
  • Developmental Biology

Cite this

Tissue-specific inactivation of p53 tumor suppression in the mouse. / Bowman, Tammy; Symonds, Holly; Gu, Liya; Yin, Chaoying; Oren, Moshe; Van Dyke, Terry.

In: Genes and Development, Vol. 10, No. 7, 01.04.1996, p. 826-835.

Research output: Contribution to journalArticle

Bowman, T, Symonds, H, Gu, L, Yin, C, Oren, M & Van Dyke, T 1996, 'Tissue-specific inactivation of p53 tumor suppression in the mouse', Genes and Development, vol. 10, no. 7, pp. 826-835. https://doi.org/10.1101/gad.10.7.826
Bowman, Tammy ; Symonds, Holly ; Gu, Liya ; Yin, Chaoying ; Oren, Moshe ; Van Dyke, Terry. / Tissue-specific inactivation of p53 tumor suppression in the mouse. In: Genes and Development. 1996 ; Vol. 10, No. 7. pp. 826-835.
@article{94039b5d24f84d02ba0b61ff0a320a3d,
title = "Tissue-specific inactivation of p53 tumor suppression in the mouse",
abstract = "The p53 gene is the most frequent target of structural and functional genetic mutations in human cancer. Thus, considerable effort has been devoted to mapping the functional domains of p53 with regard to their impact on tumorigenesis in vivo. Studies have shown that the carboxy-terminal domain of p53 is sufficient for transformation in vitro. To determine whether a transdominant-negative p53 protein could be used to elicit a tissue-specific p53-null effect in vivo, we tested whether a carboxy-terminal p53 fragment (amino acids 302-390) could abolish p53-dependent apoptosis in an established tumor progression model. We showed previously that loss of p53-dependent apoptosis accelerates brain tumorigenesis in a transgenic mouse model. Here, we show that the same effect can be elicited by expressing a dominant- negative p53 protein tissue specifically in the presence of wild-type p53. Transgenic mice in which pRb function has been disrupted and that coexpress a p53 carboxy-terminal dominant-negative fragment (p53DD) develop aggressive brain tumors mimicking genetic loss of p53 in this model. Inactivation of endogenous p53, which we show to be complexed with p53DD, results in a reduction in apoptosis and acceleration of tumorigenesis. These studies establish a mechanism for tissue-specific knock out of p53 function in vivo.",
keywords = "apoptosis, cancer, cell specificity, p53, transgenic mice",
author = "Tammy Bowman and Holly Symonds and Liya Gu and Chaoying Yin and Moshe Oren and {Van Dyke}, Terry",
year = "1996",
month = "4",
day = "1",
doi = "10.1101/gad.10.7.826",
language = "English (US)",
volume = "10",
pages = "826--835",
journal = "Genes and Development",
issn = "0890-9369",
publisher = "Cold Spring Harbor Laboratory Press",
number = "7",

}

TY - JOUR

T1 - Tissue-specific inactivation of p53 tumor suppression in the mouse

AU - Bowman, Tammy

AU - Symonds, Holly

AU - Gu, Liya

AU - Yin, Chaoying

AU - Oren, Moshe

AU - Van Dyke, Terry

PY - 1996/4/1

Y1 - 1996/4/1

N2 - The p53 gene is the most frequent target of structural and functional genetic mutations in human cancer. Thus, considerable effort has been devoted to mapping the functional domains of p53 with regard to their impact on tumorigenesis in vivo. Studies have shown that the carboxy-terminal domain of p53 is sufficient for transformation in vitro. To determine whether a transdominant-negative p53 protein could be used to elicit a tissue-specific p53-null effect in vivo, we tested whether a carboxy-terminal p53 fragment (amino acids 302-390) could abolish p53-dependent apoptosis in an established tumor progression model. We showed previously that loss of p53-dependent apoptosis accelerates brain tumorigenesis in a transgenic mouse model. Here, we show that the same effect can be elicited by expressing a dominant- negative p53 protein tissue specifically in the presence of wild-type p53. Transgenic mice in which pRb function has been disrupted and that coexpress a p53 carboxy-terminal dominant-negative fragment (p53DD) develop aggressive brain tumors mimicking genetic loss of p53 in this model. Inactivation of endogenous p53, which we show to be complexed with p53DD, results in a reduction in apoptosis and acceleration of tumorigenesis. These studies establish a mechanism for tissue-specific knock out of p53 function in vivo.

AB - The p53 gene is the most frequent target of structural and functional genetic mutations in human cancer. Thus, considerable effort has been devoted to mapping the functional domains of p53 with regard to their impact on tumorigenesis in vivo. Studies have shown that the carboxy-terminal domain of p53 is sufficient for transformation in vitro. To determine whether a transdominant-negative p53 protein could be used to elicit a tissue-specific p53-null effect in vivo, we tested whether a carboxy-terminal p53 fragment (amino acids 302-390) could abolish p53-dependent apoptosis in an established tumor progression model. We showed previously that loss of p53-dependent apoptosis accelerates brain tumorigenesis in a transgenic mouse model. Here, we show that the same effect can be elicited by expressing a dominant- negative p53 protein tissue specifically in the presence of wild-type p53. Transgenic mice in which pRb function has been disrupted and that coexpress a p53 carboxy-terminal dominant-negative fragment (p53DD) develop aggressive brain tumors mimicking genetic loss of p53 in this model. Inactivation of endogenous p53, which we show to be complexed with p53DD, results in a reduction in apoptosis and acceleration of tumorigenesis. These studies establish a mechanism for tissue-specific knock out of p53 function in vivo.

KW - apoptosis

KW - cancer

KW - cell specificity

KW - p53

KW - transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=0029916320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029916320&partnerID=8YFLogxK

U2 - 10.1101/gad.10.7.826

DO - 10.1101/gad.10.7.826

M3 - Article

VL - 10

SP - 826

EP - 835

JO - Genes and Development

JF - Genes and Development

SN - 0890-9369

IS - 7

ER -